Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Integral Diagnostics Ltd. ( (AU:IDX) ) has shared an update.
Integral Diagnostics Ltd. has announced the issuance of 296,527 performance rights under an employee incentive scheme, which are unquoted and subject to transfer restrictions. This move is part of the company’s strategy to incentivize and retain talent, potentially enhancing its operational capabilities and market position in the diagnostic imaging sector.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. operates in the healthcare industry, providing diagnostic imaging services. The company focuses on delivering high-quality radiology services across Australia and New Zealand, catering to both public and private healthcare sectors.
Average Trading Volume: 971,359
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$913.7M
Learn more about IDX stock on TipRanks’ Stock Analysis page.